NIH launched the new NIH Grants and Funding website in September. Designed with the needs of the extramural research community in mind, the new site is intended to enhance your journey through the NIH grants process with a modernized interface and powerful features to make finding critical information easier than ever. 

A key change involves a redesign of the NIH Guide for Grants and Contracts and related funding information. The new tools reduce reliance on activity codes and other NIH jargon to help you explore opportunities for funding in a more intuitive way.Continue reading→

COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies

Approval is supported by data from the EMERGENT clinical program demonstrating statistically significant reductions of schizophrenia symptoms

The safety and tolerability profile of COBENFY has been established across acute and long-term trials in schizophrenia
Continue reading→

TEMPE, Ariz., Sept. 24, 2024 (GLOBE NEWSWIRE) — Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, announced today that it received a 2024 AZBio™ Fast Lane Award from the Arizona Bioindustry Association (AZBio).  Each year a select group of Arizona-based life science companies are recognized for the progress they are making to develop and deliver health innovations. Nectero Medical accepted the award at the 20^th Annual AZBio Awards Dinner held on Wednesday, September 18^th at the Phoenix Convention Center as part of Arizona Bioscience Week, which is presented by AZBio and the Arizona Commerce Authority.Continue reading→

Presented by AZBio and the Arizona Commerce Authority

Continue reading→

Focus on Lyme and Tulane University License Groundbreaking Diagnostic Technology to Aces Diagnostics Inc.Continue reading→

Continue reading→

LOS ANGELES — City of Hope^®, one of the largest and most advanced cancer research and treatment organizations in the U.S. and ranked among the nation’s top 5 cancer centers by U.S. News & World Report, has received a historic $150 million gift from entrepreneurs and philanthropists A. Emmet Stephenson Jr. and his daughter Tessa Stephenson Brand to immediately fund pancreatic cancer research. Continue reading→

PHOENIX, ARIZ, September 17, 2024 – Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, Chief of Neurosurgical Oncology at Barrow Neurological Institute, and the Francis & Dionne Professor of Neurological Surgery, has been recognized as the 2024 Arizona Bioscience Researcher of the Year by the Arizona Bioindustry Association. He will receive the award at the 20th Annual AZBio Awards on Wednesday, September 18 at the Phoenix Convention Center. Dr. Sanai is being honored for his pioneering spirit and commitment to push beyond the status quo to discover new therapies for his brain tumor patients. Continue reading→

PHOENIX and FRIENDSWOOD, TX – Sept. 16, 2024 – The Arizona Bioindustry Association, Inc. (AZBio) and Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Kristen Oelschlager, R.N., Castle’s chief operating officer, has been named the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year. The award, presented by AZBio, recognizes Oelschlager for her outstanding leadership that has contributed significantly to the progression of the bioscience industry in Arizona.Continue reading→

WASHINGTON, Sept. 12, 2024 — Critical Path Institute (C-Path) successfully concluded its inaugural Global Impact Conference (CGIC) on September 11, 2024, at the Washington Marriott at Metro Center in Washington, D.C. This landmark event brought together industry leaders, regulatory agencies, academic experts, and patient advocacy groups, all dedicated to advancing drug development and regulatory science for rare diseases. Continue reading→